A Study to Investigate the Effect of Extracorporeal Shockwave Lithotripsy on Hypertension

A Prospective Randomized Study to Investigate the Effect of Extracorporeal Shockwave Lithotripsy on Blood Pressure Control in Patients With Hypertension - a Pilot Study

Having the advantages of being minimally invasive and simple, extracorporeal shock wave lithotripsy (SWL) remains one of the treatment options for renal stones less than 2cm. Although SWL is the most minimally invasive surgical approach for stone, there are still some concern about its short and long term side effect. While, there are some evidences that SWL might lead to increase in new onset hypertension, investigator's recent study suggested it might also cause worsening of blood pressure control in patient with known hypertension. Therefore, further studies are needed to confirm the initial finding. This study recruits patients who have hypertension and are currently diagnosed to have renal stone and planned for SWL, in order to to investigate the effect of SWL on blood pressure control.

After informed consent and background information have been obtained, patients will be randomized to either have routine SWL (treatment arm) or 6 months later (control arm). Group 1 patients will have blood pressure monitored for one day at home by an handy automated blood pressure measuring machine before SWL and 6 months after SWL. Group 2 patients will have blood pressure monitoring immediately and then 6 months later, just prior to the SWL.

Study Overview

• Status: Withdrawn
• Conditions: Hypertension; Renal Stone
• Intervention / Treatment: Procedure: Extracorporeal shock wave lithotripsy

Detailed Description

BACKGROUND

Extracorporeal shock wave lithotripsy (SWL) was first introduced in early 1980's for the management of urolithiasis. The advantage of being minimally invasive, when compared to other procedures for stone treatment, made SWL remain one of the treatment options for renal stones less than 2 cm in the latest guidelines.

Despite considered as the most non-invasive treatment for urinary calculi, there are still many concerns about the long-term consequence of SWL. In particular, the effect of SWL on blood pressure is still a controversy topic. In the recent study, investigator has observed approximately 20% of subjects experienced worsened blood pressure control during the 2-year follow-up period, including 20/202 (9.95%) previously non-hypertensive subjects who developed new onset hypertension. The observed incidence of new-onset hypertension was quite similar those in some reported series. In the literature, there were multiple reports, including case series and hospital data analyses, 7-9 of development of new-onset hypertension after SWL. Unfortunately, most of those studies were retrospective and used different definitions of hypertension.

But the high incidence of worsening blood pressure control, including 43 (36.4%) of 118 hypertensive subjects who required add-on antihypertensive therapies, observed in our study was alarming. Because most studies in the literature were just focused on development of new-onset hypertension, investigator's observation provides supplementary information about potential effects of SWL on pre-existing hypertension. In general, the average annual incidence of add-on pharmacotherapy among local hypertensive patients was 4.71-6.41%. 10 Therefore, the add-on therapy rate of 36.4% during the 2-year follow-up was much higher than that in the general population. Unfortunately, investigator did not include a non-interventional arm for comparison in the previous study and could not conclude that this outcome was solely attributable to SWL.

Therefore, investigator would like to propose a prospective study to assess the effect SWL on the blood pressure control in patients with known hypertension. Investigator hope the study results will provide additional information on the long-term effect of SWL on patients.

OJECTIVES

To investigate the effect of extracorporeal shockwave lithotripsy on the effect of change in blood pressure in patients with known hypertension.

STUDY PROTOCOL:

Patients fulfilled the inclusion and exclusion criteria specific to this study will be prospectively recruited. After obtaining informed consent, patients will be randomized to either treatment group or control group.

Baseline information, including age, years of diagnosed to have hypertension, current medical usage, other comorbidities, BMI etc. will be collected from patients. All SWL would be performed in the Lithotripsy and Uro-investigation Centre of the Prince of Wales Hospital, and treated by Modulith SLX-F2 Connect (Storz Medical, Switzerland), an electromagnetic lithotriptor. The treatment would be performed as standard care in our hospital. After SWL, the patient would be follow-up in clinic as usual. During the 6 months study period, patients are strongly advised to avoid change in hypertensive medication.

Blood pressure assessment:

During each blood pressure assessment, the following procedure will be performed:

1. 24-hour blood pressure monitoring - 24-h non-invasive ambulatory BP and HR monitoring was performed using a validated device and followed the recommended approached. 11 The blood pressure measurement would be programmed to measure BP every 15 min. Each recording will be started in the morning and performed throughout a full 24-h period, during which subjects are allowed to follow their normal daily routine. The analysis of 24-h BP recordings are preceded by removal of artifacts, according to previously described editing criteria. 12 Recordings are excluded from the analysis when > 10% of all readings or more than one reading per hour is missed. Computed analysis of the individual recordings provided 24-h, night-time (23.00-07.00 h), morning-time (0.7.00-12.00 h), and afternoon/evening-time (12.00- 23.00 h) mean values of SBP, DBP, and HR.
2. Clinic blood pressure measurement At each visit, blood pressure will be measured after patient rested for more than 10 minutes, with repeated measurement 5 minutes apart. The mean blood pressure will be recorded.
3. Any changes in antihypertensive drugs and reasons
4. Any adverse events.

The result collected will be used for further analysis

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Hong Kong
  • Shatin, Hong Kong
    • Prince of Wales Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Renal calculi of size 5-15 mm in maximal diameter and considered as suitable for SWL
• Patient with known hypertension and on regular medical treatment with regular follow-up.
• Patient with stable hypertension for at least 3 months

Exclusion Criteria:

• Patients had previous SWL, kidney surgery, percutaneous nephrolithotomy, etc.
• Patients with stones obviously required more than one section of SWL

Study Plan

How is the study designed?

Design Details

• Primary Purpose: DIAGNOSTIC
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Treatment Arm; immediate extracorporeal shock wave lithotripsy - subject will have SWL arranged in the next available list	Procedure: Extracorporeal shock wave lithotripsy; A minimally invasive treatment for renal stone which was first introduced in early 1980's. It tries to fragment the renal stones by high-energy shockwave at the kidney from the outside.
NO_INTERVENTION: Control Arm; delayed extracorporeal shock wave lithotripsy - subject will have SWL done 6 months later

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The changes in mean 24hr systolic and diastolic blood pressure measurement	For treatment arm, the changes in mean 24hr systolic and diastolic blood pressure measurement before SWL and 6 monthes after SWL For control arm, the changes in mean 24hr systolic and diastolic blood pressure measurement right after randomization and in 6 months.	Baseline, 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in mean night time diastolic and systolic blood pressure	For treatment arm, the changes in mean night time systolic and diastolic blood pressure measurement before SWL and 6 monthes after SWL For control arm, the changes in mean night time systolic and diastolic blood pressure measurement right after randomization and in 6 months.	Baseline, 6 months
Change in mean night time heart rate	For treatment arm, the changes in mean heart rate before SWL and 6 monthes after SWL For control arm, the changes in mean night time heart rate right after randomization and in 6 months.	Baseline, 6 months
Change in mean morning-time diastolic and systolic blood pressure	For treatment arm, the changes in mean morning-time systolic and diastolic blood pressure measurement before SWL and 6 monthes after SWL For control arm, the changes in mean morning-time systolic and diastolic blood pressure measurement right after randomization and in 6 months.	Baseline, 6 months
Change in mean morning-time heart rate	For treatment arm, the changes in mean morning-time heart rate before SWL and 6 monthes after SWL For control arm, the changes in mean morning-time heart rate right after randomization and in 6 months.	Baseline, 6 months
Change in mean afternoon/evening diastolic and systolic blood pressure	For treatment arm, the changes in mean afternoon/evening systolic and diastolic blood pressure measurement before SWL and 6 monthes after SWL For control arm, the changes in mean afternoon/evening systolic and diastolic blood pressure measurement right after randomization and in 6 months.	Baseline, 6 months
Change in mean afternoon/evening heart rate	For treatment arm, the changes in mean afternoon/evening heart rate before SWL and 6 monthes after SWL For control arm, the changes in mean afternoon/evening heart rate right after randomization and in 6 months.	Baseline, 6 months
Change in mean 24hr heart rate	For treatment arm, the changes in mean 24hr heart rate measurement before SWL and 6 monthes after SWL For control arm, the changes in mean 24hr heart rate measurement right after randomization and in 6 months.	Baseline, 6 months
The need of add-on therapy for hypertension	Any add-on anti-hypertensive drugs in 6 months time	6 months
Any adverse effects after SWL	Any adverse effects comparing the treatment arm and control arm during study period	6 months

Collaborators and Investigators

• Sponsor: Chinese University of Hong Kong
• Investigators: Principal Investigator: Chi Fai NG, Md, CUHK

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): January 1, 2021
• Primary Completion (ANTICIPATED): April 30, 2022
• Study Completion (ANTICIPATED): October 30, 2022

Study Registration Dates

• First Submitted: October 15, 2018
• First Submitted That Met QC Criteria: October 19, 2018
• First Posted (ACTUAL): October 22, 2018

Study Record Updates

• Last Update Posted (ACTUAL): February 25, 2021
• Last Update Submitted That Met QC Criteria: February 23, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Keywords: Renal stone; Worsening hypertension
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Kidney Diseases; Urologic Diseases; Pathological Conditions, Anatomical; Urolithiasis; Urinary Calculi; Calculi; Hypertension; Kidney Calculi; Nephrolithiasis
• Other Study ID Numbers: CRE 2018.276

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: No individual participant data will be shared to other researchers outside CUHK Urology unit

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No